Stock Track | Myriad Genetics Plummets 25% on Q4 Earnings Decline and Q1 Guidance Miss amid UnitedHealthcare Headwinds

Stock Track

Feb 25, 2025

Myriad Genetics (MYGN) stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.

For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).

Myriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. However, the weaker-than-expected first-quarter guidance and the potential impact of UnitedHealthcare's decision not to cover the company's GeneSight test weighed heavily on the stock. Analysts at UBS also cut their price target on the stock to $16 from $18, citing concerns over the UnitedHealthcare headwinds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118650509"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118650509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118650509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118650509","market":"us","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Plummets 25% on Q4 Earnings Decline and Q1 Guidance Miss amid UnitedHealthcare Headwinds","media":"Stock Track","content":"<p>Myriad Genetics (MYGN) stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.</p>\n\n<p>For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).</p>\n\n<p>Myriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. However, the weaker-than-expected first-quarter guidance and the potential impact of UnitedHealthcare's decision not to cover the company's GeneSight test weighed heavily on the stock. Analysts at UBS also cut their price target on the stock to $16 from $18, citing concerns over the UnitedHealthcare headwinds.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Plummets 25% on Q4 Earnings Decline and Q1 Guidance Miss amid UnitedHealthcare Headwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Plummets 25% on Q4 Earnings Decline and Q1 Guidance Miss amid UnitedHealthcare Headwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Myriad Genetics (MYGN) stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.</p>\n\n<p>For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).</p>\n\n<p>Myriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. However, the weaker-than-expected first-quarter guidance and the potential impact of UnitedHealthcare's decision not to cover the company's GeneSight test weighed heavily on the stock. Analysts at UBS also cut their price target on the stock to $16 from $18, citing concerns over the UnitedHealthcare headwinds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1118650509","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118650509","pubTimestamp":1740494075,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"由于UnitedHealthcare的不利因素，Myriad Genetics第四季度盈利下降且第一季度指引未达预期，股价暴跌25%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) stock plummeted over 25% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.\nFor the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).\nMyriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. However, the weaker-than-expected first-quarter guidance and the potential impact of UnitedHealthcare's decision not to cover the company's GeneSight test weighed heavily on the stock. Analysts at UBS also cut their price target on the stock to $16 from $18, citing concerns over the UnitedHealthcare headwinds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}